Faron Pharmaceuticals - Innovative medical solutions (Part 2)

There’s no such thing as a free lunch. Whatever Faron didn’t screw up in the previous share issue, HCM is carrying on with.

Finally, both of the above understand that they are driving Faron into a total dead end. As long as HCM keeps dumping these discount shares onto the bid side, Faron’s share price won’t start rising—everyone loses in that scenario, perhaps most of all HCM right now. We won’t see a real rebound until the trial results come in—or through successful partnership negotiations. HCM naturally aims to maximize its profits—a pause in selling & deferring payments would support this goal.

IMHO

7 Likes